Compare ATRC & MGNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATRC | MGNI |
|---|---|---|
| Founded | 2000 | 2007 |
| Country | United States | United States |
| Employees | N/A | 514 |
| Industry | Medical/Dental Instruments | Computer Software: Programming Data Processing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.2B |
| IPO Year | 2005 | 2014 |
| Metric | ATRC | MGNI |
|---|---|---|
| Price | $29.95 | $12.65 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 9 |
| Target Price | ★ $51.17 | $25.22 |
| AVG Volume (30 Days) | 545.5K | ★ 2.1M |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 74.74 | ★ 493.75 |
| EPS | N/A | ★ 0.95 |
| Revenue | ★ $201,630,000.00 | $156,414,000.00 |
| Revenue This Year | $15.17 | $6.33 |
| Revenue Next Year | $12.42 | $9.73 |
| P/E Ratio | ★ N/A | $12.99 |
| Revenue Growth | 15.40 | ★ 25.45 |
| 52 Week Low | $28.32 | $8.22 |
| 52 Week High | $43.18 | $26.65 |
| Indicator | ATRC | MGNI |
|---|---|---|
| Relative Strength Index (RSI) | 42.21 | 47.49 |
| Support Level | $28.69 | $11.81 |
| Resistance Level | $32.85 | $17.16 |
| Average True Range (ATR) | 1.14 | 0.58 |
| MACD | 0.20 | -0.02 |
| Stochastic Oscillator | 37.59 | 31.21 |
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.
Magnite is a supply-side advertising platform that provides technology and yield management solutions to content publishers, enabling them to monetize their digital advertising inventory. Magnite receives a percentage of all advertising inventory that it sells. 43% of Magnite's revenue is derived from connected television, or CTV, streaming platforms, 40% from mobile applications, and the remainder from general websites. Beyond the typical monetization responsibilities inherent to an SSP, Magnite also provides upstream advertising servers to CTV publishers, allowing them to have granular control over direct-sold, programmatic guaranteed, and open-auction logic. Magnite competes with other independent SSPs, supply path optimization solutions, and closed ecosystems like Meta.